ZA200805011B - Water-soluble benzoazepine compound and its pharmaceutical composition - Google Patents

Water-soluble benzoazepine compound and its pharmaceutical composition

Info

Publication number
ZA200805011B
ZA200805011B ZA200805011A ZA200805011A ZA200805011B ZA 200805011 B ZA200805011 B ZA 200805011B ZA 200805011 A ZA200805011 A ZA 200805011A ZA 200805011 A ZA200805011 A ZA 200805011A ZA 200805011 B ZA200805011 B ZA 200805011B
Authority
ZA
South Africa
Prior art keywords
soluble
water
pharmaceutical composition
benzoazepine compound
benzoazepine
Prior art date
Application number
ZA200805011A
Other languages
English (en)
Inventor
Komatsu Makoto
Goto Fumitaka
Menjo Yasuhiro
Yamada Keigo
Matsuda Takakuni
Kato Yusuke
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37877008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200805011(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of ZA200805011B publication Critical patent/ZA200805011B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532Seven-(or more) membered rings
    • C07F9/5535Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532Seven-(or more) membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
ZA200805011A 2005-12-27 2006-12-22 Water-soluble benzoazepine compound and its pharmaceutical composition ZA200805011B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005375457 2005-12-27

Publications (1)

Publication Number Publication Date
ZA200805011B true ZA200805011B (en) 2009-11-25

Family

ID=37877008

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805011A ZA200805011B (en) 2005-12-27 2006-12-22 Water-soluble benzoazepine compound and its pharmaceutical composition

Country Status (23)

Country Link
US (6) US20100004206A1 (pt)
EP (2) EP2674436A1 (pt)
JP (2) JP4644287B2 (pt)
KR (1) KR101008931B1 (pt)
CN (1) CN101346390B (pt)
AR (2) AR058737A1 (pt)
AU (1) AU2006330277B2 (pt)
BR (1) BRPI0620715A2 (pt)
CA (1) CA2633929A1 (pt)
CY (1) CY1116208T1 (pt)
DK (1) DK1968990T3 (pt)
ES (1) ES2533007T3 (pt)
HK (1) HK1121461A1 (pt)
IL (1) IL191935A (pt)
MY (1) MY146042A (pt)
NO (1) NO342436B1 (pt)
PL (1) PL1968990T3 (pt)
PT (1) PT1968990E (pt)
RU (1) RU2418804C2 (pt)
SI (1) SI1968990T1 (pt)
TW (1) TWI323257B (pt)
WO (1) WO2007074915A1 (pt)
ZA (1) ZA200805011B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
JP5590780B2 (ja) * 2007-06-26 2014-09-17 大塚製薬株式会社 医薬
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
CN102020609A (zh) * 2009-09-17 2011-04-20 北京本草天源药物研究院 托伐普坦晶体或无定形物及其制备方法
DE102010041263A1 (de) * 2010-09-23 2012-03-29 Siemens Medical Instruments Pte. Ltd. Hörgerätegehäuse mit Dichtungslippe
TWI704919B (zh) * 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
NZ630346A (en) * 2012-12-28 2016-06-24 Otsuka Pharma Co Ltd Injectable depot formulation comprising optically active tolvaptan and process of producing the same
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及/或治療多囊腎病之藥物
CA3029374A1 (en) * 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Phosphorus prodrugs of sgc stimulators
JP2021014406A (ja) * 2017-10-25 2021-02-12 トーアエイヨー株式会社 バソプレシン受容体拮抗剤
EA202192088A1 (ru) * 2019-01-30 2021-11-03 Оцука Фармасьютикал Ко., Лтд. Способ получения бензоазепинового соединения
EA202192635A1 (ru) * 2019-03-28 2021-12-10 Оцука Фармасьютикал Ко., Лтд. Фармацевтическая композиция, содержащая бензоазепиновое соединение
EP3946259A1 (en) 2019-03-28 2022-02-09 Otsuka Pharmaceutical Co., Ltd. Benzoazepine compound-containing freeze-dried composition
CN116744935A (zh) 2021-02-10 2023-09-12 上海森辉医药有限公司 苯并氮杂䓬类化合物及其制备方法和医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5753677A (en) * 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
CA2066104C (en) 1991-04-19 2003-05-27 Hidenori Ogawa Benzazepine derivatives as vasopressin antagonists
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
JP4210355B2 (ja) 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
US5972882A (en) * 1997-12-15 1999-10-26 University Of Kansas Medical Center Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
TWI322689B (en) 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
CY1116208T1 (el) 2017-02-08
NO342436B1 (no) 2018-05-22
US20120277188A1 (en) 2012-11-01
NO20082630L (no) 2008-09-16
BRPI0620715A2 (pt) 2011-11-22
SI1968990T1 (sl) 2015-05-29
US9809609B2 (en) 2017-11-07
JP5550522B2 (ja) 2014-07-16
HK1121461A1 (en) 2009-04-24
IL191935A (en) 2013-07-31
US9303052B2 (en) 2016-04-05
EP1968990A1 (en) 2008-09-17
TWI323257B (en) 2010-04-11
AR107193A2 (es) 2018-03-28
CA2633929A1 (en) 2007-07-05
US20110098250A1 (en) 2011-04-28
JP4644287B2 (ja) 2011-03-02
RU2418804C2 (ru) 2011-05-20
AU2006330277A1 (en) 2007-07-05
PT1968990E (pt) 2015-03-16
CN101346390B (zh) 2011-11-09
AR058737A1 (es) 2008-02-20
US20100004206A1 (en) 2010-01-07
EP2674436A1 (en) 2013-12-18
US20120277189A1 (en) 2012-11-01
DK1968990T3 (da) 2015-04-27
KR20080078916A (ko) 2008-08-28
ES2533007T3 (es) 2015-04-06
RU2008130887A (ru) 2010-02-10
MY146042A (en) 2012-06-15
PL1968990T3 (pl) 2015-06-30
US20110082110A1 (en) 2011-04-07
WO2007074915A8 (en) 2007-11-08
TW200734309A (en) 2007-09-16
JP2011046731A (ja) 2011-03-10
IL191935A0 (en) 2008-12-29
JP2009521397A (ja) 2009-06-04
KR101008931B1 (ko) 2011-01-17
CN101346390A (zh) 2009-01-14
WO2007074915A1 (en) 2007-07-05
EP1968990B1 (en) 2015-02-11
US20130331358A1 (en) 2013-12-12
AU2006330277B2 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
IL191935A0 (en) Water-soluble benzoazepine compound and its pharmaceutical composition
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
EP1857489A4 (en) MICROPARTICLE AND PHARMACEUTICAL COMPOSITION
IL188941A0 (en) Pyrazinolyguanidine derivatives and pharmaceutical compositions containing the same
HK1121162A1 (en) Oxazole compound and pharmaceutical composition
IL186738A0 (en) Pyrizole derivatives and pharmaceutical compositions containing the same
IL183919A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
IL189782A0 (en) Sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
PL2033629T3 (pl) Stała kompozycja farmaceutyczna zawierająca walsartan
IL186336A0 (en) Pharmaceutical composition
IL183986A0 (en) Pharmaceutical compounds and compositions
ZA200803283B (en) Pharmaceutical gallium compositions and methods
IL184996A0 (en) Dihydroimidazothiazole derivatives and pharmaceutical compositions containing the same
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
EP2070919A4 (en) SPIROCHINONE COMPOUND AND PHARMACEUTICAL COMPOSITION
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
IL189172A0 (en) Cercosporamide derivatives and pharmaceutical compositions containing the same
ZA200705131B (en) Solid pharmaceutical composition comprising valsartan
ZA200709692B (en) Antineoplastic compounds and pharmaceutical compositions thereof
IL186337A0 (en) Stannsoporfin compositions and administration
IL188011A0 (en) Spiro-benzimidazole derivatives and pharmaceutical compositions containing the same
EP1937292A4 (en) LOPAP-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
EP1865777A4 (en) STANNSOPORFIN COMPOSITIONS AND ADMINISTRATION